Journal
NEUROSCIENCE RESEARCH
Volume 41, Issue 4, Pages 397-399Publisher
ELSEVIER SCI IRELAND LTD
DOI: 10.1016/S0168-0102(01)00298-X
Keywords
zonisamide; Parkinson's disease; levodopa; anticonvulsant
Categories
Ask authors/readers for more resources
Zonisamide (ZNS) is a generally well tolerated anticonvulsant that has beneficial effects on Parkinson's disease (PD). ZNS (300 mg/day) given to a patient with PD who incidentally had convulsive attacks, ameliorated the attacks and, surprisingly, his parkinsonian symptoms. We, therefore, carried out an open trial of ZNS on nine patients with PD. Patients were given 50-200 mg/day ZNS in addition to their anti-PD drugs. Seven clearly showed lessening of symptoms, especially wearing-off. We speculate that long lasting activation of dopamine synthesis by ZNS ameliorates parkinsonian symptoms, in particular wearing-off. (C) 2001 Elsevier Science Ireland Ltd and the Japan Neuroscience Society. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available